INCYTE CORP
Close on Oct 19, 2026
- Market cap
- $23.58B
- P/E (TTM)
- 14.4
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 28, 2026 | Before market open | $1.67B | $2.81 | $3.09 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | Before market open | $1.27B | $1.47 | $1.81 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 10, 2026 | Before market open | $1.51B | $1.46 | $1.80 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $1.37B | $2.11 | $2.26 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $1.22B | $2.04 | $1.57 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 29, 2025 | Before market open | $1.05B | $0.80 | $1.16 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 10, 2025 | Before market open | $1.20B | $1.02 | $1.43 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | Before market open | $1.14B | $0.54 | $1.07 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 13, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 28, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total GAAP R&D and SG&A operating expenseGAAP | full year 2026 | $4.92B to $5.00B | Raised |
| Jakafi net sales | fiscal year 2026 | $3.22B to $3.27B | New |
| total non-GAAP R&D and SG&A operating expensenon-GAAP | full year 2026 | $4.63B to $4.70B | Raised |
| Hematology and Oncology net sales | full year 2026 | $860.00M to $890.00M | Lowered |
| Opzelura net sales | full year 2026 | $1.05B to $1.10B | Lowered |
| total net sales | full year 2026 | $5.13B to $5.26B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Incyte filed with the SEC
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Other events · EX-99.1 to Form 8-K
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2025 First Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results,
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Announces Intention to Buy Back up to
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Incyte Reports 2024 First Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results,
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2023 First Quarter Financial Results and
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results,
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key
Results of operations · EX-99.1 to Form 8-K
Incyte Reports 2021 Fourth Quarter and Year-end Financial Results, and
Results of operations · EX-99.1 to Form 8-K
WILMINGTON, Del. – November 2, 2021 – This morning,
Regulation FD disclosure · EX-99.1 to Form 8-K
Incyte Reports 2021 Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K